vs
渤健（BIIB）与纽约梅隆银行（BK）财务数据对比。点击上方公司名可切换其他公司
渤健的季度营收约是纽约梅隆银行的1.7倍（$2.3B vs $1.3B），纽约梅隆银行净利率更高（108.5% vs -2.1%，领先110.7%），纽约梅隆银行同比增速更快（12.7% vs -7.1%），纽约梅隆银行自由现金流更多（$4.7B vs $468.0M），过去两年纽约梅隆银行的营收复合增速更高（13.8% vs -0.2%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
纽约梅隆银行是总部位于美国纽约的全球性金融服务机构，2007年7月由纽约银行与梅隆金融公司合并组建而成，业务覆盖全球众多市场，为机构、企业及个人客户提供专业金融服务，在资产管理、证券服务等领域拥有领先的行业地位。
BIIB vs BK — 直观对比
营收规模更大
BIIB
是对方的1.7倍
$1.3B
营收增速更快
BK
高出19.9%
-7.1%
净利率更高
BK
高出110.7%
-2.1%
自由现金流更多
BK
多$4.3B
$468.0M
两年增速更快
BK
近两年复合增速
-0.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.3B | $1.3B |
| 净利润 | $-48.9M | $1.5B |
| 毛利率 | 78.3% | — |
| 营业利润率 | -2.5% | — |
| 净利率 | -2.1% | 108.5% |
| 营收同比 | -7.1% | 12.7% |
| 净利润同比 | -118.3% | 26.5% |
| 每股收益（稀释后） | $-0.35 | $2.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBBK
| Q4 25 | $2.3B | $1.3B | ||
| Q3 25 | $2.5B | $1.2B | ||
| Q2 25 | $2.6B | $1.2B | ||
| Q1 25 | $2.4B | $1.2B | ||
| Q4 24 | $2.5B | $1.2B | ||
| Q3 24 | $2.5B | $1.0B | ||
| Q2 24 | $2.5B | $1.0B | ||
| Q1 24 | $2.3B | $1.0B |
净利润BIIBBK
| Q4 25 | $-48.9M | $1.5B | ||
| Q3 25 | $466.5M | $1.4B | ||
| Q2 25 | $634.8M | $1.4B | ||
| Q1 25 | $240.5M | $1.2B | ||
| Q4 24 | $266.7M | $1.2B | ||
| Q3 24 | $388.5M | $1.2B | ||
| Q2 24 | $583.6M | $1.2B | ||
| Q1 24 | $393.4M | $1.0B |
毛利率BIIBBK
| Q4 25 | 78.3% | — | ||
| Q3 25 | 73.4% | — | ||
| Q2 25 | 77.1% | — | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 76.2% | — | ||
| Q3 24 | 74.1% | — | ||
| Q2 24 | 77.8% | — | ||
| Q1 24 | 76.3% | — |
营业利润率BIIBBK
| Q4 25 | -2.5% | — | ||
| Q3 25 | 22.0% | — | ||
| Q2 25 | 28.1% | — | ||
| Q1 25 | 12.8% | — | ||
| Q4 24 | 11.9% | — | ||
| Q3 24 | 18.3% | — | ||
| Q2 24 | 28.3% | — | ||
| Q1 24 | 20.3% | — |
净利率BIIBBK
| Q4 25 | -2.1% | 108.5% | ||
| Q3 25 | 18.4% | 116.9% | ||
| Q2 25 | 24.0% | 118.3% | ||
| Q1 25 | 9.9% | 105.3% | ||
| Q4 24 | 10.9% | 96.7% | ||
| Q3 24 | 15.8% | 112.8% | ||
| Q2 24 | 23.7% | 113.4% | ||
| Q1 24 | 17.2% | 98.6% |
每股收益（稀释后）BIIBBK
| Q4 25 | $-0.35 | $2.01 | ||
| Q3 25 | $3.17 | $1.88 | ||
| Q2 25 | $4.33 | $1.93 | ||
| Q1 25 | $1.64 | $1.58 | ||
| Q4 24 | $1.82 | $1.53 | ||
| Q3 24 | $2.66 | $1.50 | ||
| Q2 24 | $4.00 | $1.52 | ||
| Q1 24 | $2.70 | $1.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $5.1B |
| 总债务越低越好 | $6.3B | $31.9B |
| 股东权益账面价值 | $18.3B | $44.3B |
| 总资产 | $29.4B | $472.3B |
| 负债/权益比越低杠杆越低 | 0.34× | 0.72× |
8季度趋势，按日历期对齐
现金及短期投资BIIBBK
| Q4 25 | — | $5.1B | ||
| Q3 25 | — | $5.1B | ||
| Q2 25 | — | $5.7B | ||
| Q1 25 | — | $5.4B | ||
| Q4 24 | — | $4.2B | ||
| Q3 24 | — | $6.2B | ||
| Q2 24 | — | $5.3B | ||
| Q1 24 | — | $5.3B |
总债务BIIBBK
| Q4 25 | $6.3B | $31.9B | ||
| Q3 25 | $6.3B | $32.3B | ||
| Q2 25 | $6.3B | $33.4B | ||
| Q1 25 | $4.5B | $30.9B | ||
| Q4 24 | $6.3B | $30.9B | ||
| Q3 24 | $4.5B | $33.2B | ||
| Q2 24 | $6.3B | $30.9B | ||
| Q1 24 | $6.3B | $32.4B |
股东权益BIIBBK
| Q4 25 | $18.3B | $44.3B | ||
| Q3 25 | $18.2B | $43.9B | ||
| Q2 25 | $17.6B | $44.0B | ||
| Q1 25 | $17.0B | $43.1B | ||
| Q4 24 | $16.7B | $41.3B | ||
| Q3 24 | $16.4B | $42.0B | ||
| Q2 24 | $15.9B | $40.8B | ||
| Q1 24 | $15.2B | $40.6B |
总资产BIIBBK
| Q4 25 | $29.4B | $472.3B | ||
| Q3 25 | $29.2B | $455.3B | ||
| Q2 25 | $28.3B | $485.8B | ||
| Q1 25 | $28.0B | $440.7B | ||
| Q4 24 | $28.0B | $416.1B | ||
| Q3 24 | $28.3B | $427.5B | ||
| Q2 24 | $26.8B | $428.5B | ||
| Q1 24 | $26.6B | $434.7B |
负债/权益比BIIBBK
| Q4 25 | 0.34× | 0.72× | ||
| Q3 25 | 0.35× | 0.74× | ||
| Q2 25 | 0.36× | 0.76× | ||
| Q1 25 | 0.27× | 0.72× | ||
| Q4 24 | 0.38× | 0.75× | ||
| Q3 24 | 0.28× | 0.79× | ||
| Q2 24 | 0.40× | 0.76× | ||
| Q1 24 | 0.41× | 0.80× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $511.9M | $5.2B |
| 自由现金流经营现金流 - 资本支出 | $468.0M | $4.7B |
| 自由现金流率自由现金流/营收 | 20.5% | 352.8% |
| 资本支出强度资本支出/营收 | 1.9% | 32.4% |
| 现金转化率经营现金流/净利润 | — | 3.55× |
| 过去12个月自由现金流最近4个季度 | $2.1B | $5.2B |
8季度趋势，按日历期对齐
经营现金流BIIBBK
| Q4 25 | $511.9M | $5.2B | ||
| Q3 25 | $1.3B | $-1.1B | ||
| Q2 25 | $160.9M | $2.2B | ||
| Q1 25 | $259.3M | $412.0M | ||
| Q4 24 | $760.9M | $1.6B | ||
| Q3 24 | $935.6M | $-312.0M | ||
| Q2 24 | $625.8M | $2.1B | ||
| Q1 24 | $553.2M | $-2.7B |
自由现金流BIIBBK
| Q4 25 | $468.0M | $4.7B | ||
| Q3 25 | $1.2B | $-1.5B | ||
| Q2 25 | $134.3M | $1.8B | ||
| Q1 25 | $222.2M | $92.0M | ||
| Q4 24 | $721.6M | $1.1B | ||
| Q3 24 | $900.6M | $-687.0M | ||
| Q2 24 | $592.3M | $1.7B | ||
| Q1 24 | $507.3M | $-3.0B |
自由现金流率BIIBBK
| Q4 25 | 20.5% | 352.8% | ||
| Q3 25 | 48.4% | -121.5% | ||
| Q2 25 | 5.1% | 152.8% | ||
| Q1 25 | 9.1% | 7.9% | ||
| Q4 24 | 29.4% | 95.2% | ||
| Q3 24 | 36.5% | -65.6% | ||
| Q2 24 | 24.0% | 169.6% | ||
| Q1 24 | 22.1% | -286.4% |
资本支出强度BIIBBK
| Q4 25 | 1.9% | 32.4% | ||
| Q3 25 | 1.8% | 35.4% | ||
| Q2 25 | 1.0% | 29.8% | ||
| Q1 25 | 1.5% | 27.6% | ||
| Q4 24 | 1.6% | 34.6% | ||
| Q3 24 | 1.4% | 35.8% | ||
| Q2 24 | 1.4% | 37.1% | ||
| Q1 24 | 2.0% | 28.7% |
现金转化率BIIBBK
| Q4 25 | — | 3.55× | ||
| Q3 25 | 2.73× | -0.74× | ||
| Q2 25 | 0.25× | 1.54× | ||
| Q1 25 | 1.08× | 0.34× | ||
| Q4 24 | 2.85× | 1.34× | ||
| Q3 24 | 2.41× | -0.26× | ||
| Q2 24 | 1.07× | 1.82× | ||
| Q1 24 | 1.41× | -2.61× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
BK
暂无分部数据
